Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 participants, all of whom completed the study — none dropped out. The trial was looking at how well people could hear and repeat single-syllable words in a quiet environment. Specifically, it was comparing three different sound-coding strategies (ways that a hearing device processes sound): a standard approach called ACE, and two newer approaches called SPACE and OPAL-SPACE. The reported data shows that participants were scored on the percentage of single-syllable words they could correctly repeat back. For the ACE strategy, the reported average score was 51% of words repeated correctly. For the SPACE strategy, the reported average score was 51.25%, and for the OPAL-SPACE strategy, it was 48.50%. All three scores fell within a fairly narrow range of each other, between roughly 48% and 52% out of a possible score of 0% to 100%. It is worth noting that only 8 people took part, which is a very small number. No other outcome measure data was reported in the results submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Hearing Loss Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You currently use a Nucleus cochlear implant that has been officially approved, and it helps you understand spoken words without lip-reading.
- Children must be older than 5 years and under 18 years old when joining the study (available in Belgium only for children).
- Adults must be 18 years or older when joining the study (available in Belgium and Australia).
- You (or your parent/legal guardian, if you are a child) must speak the language used in the study tests fluently.
- You (or your parent/legal guardian, if you are a child) must be willing and able to sign a written consent form to take part.
Who may not be able to join:
- People who are unable or unwilling to follow the study requirements, as decided by the study doctor.
- People who have additional health conditions that could prevent them from taking part in the hearing tests (confirm with trial site).
- People who work at the trial site and are directly involved in this study, or their close family members (spouse, parent, child, or sibling).
- People who work for Cochlear (the company running the trial) or for organisations hired by Cochlear to help run this study.
- People who are currently taking part in, or have taken part in within the last 30 days, another clinical trial testing an unapproved drug or medical device.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Komal Arora, Cochlear
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Monosyllabic Word in Quiet Scores.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.